ByTrending Posts
How Are NUS and UC San Diego Using…
Key Highlights: AI-Powered Personalization: Unlocking Sex-Specific Drug EfficacyThe collaboration between the National University of Singapore’s WisDM and UC…
Will XtalPi’s AI-Driven Acquisition of LCC Redraw the…
Key Highlights: AI Meets Chiral Chemistry in Strategic UK AcquisitionXtalPi Holdings Ltd. (HKEX: 2228), the AI-powered drug discovery…
Is DeepCure’s AI-Designed Oral STAT6 Inhibitor the Next…
Key Highlights: Oral Option for Dupilumab-Class PatientsDeepCure’s newly nominated candidate DC-15442 offers a breakthrough alternative to injectable biologics…
How Novo Nordisk and Deep Apple’s $812M AI-Powered…
Key Highlights: A Bold Break from Incretin DependencyNovo Nordisk’s new alliance with Deep Apple Therapeutics marks a critical…
How Will HEALWELL AI and Orion Health Transform…
Key Highlights: Strategic Expansion into US Healthcare MarketHEALWELL AI Inc., following its acquisition of Orion Health, announces a…
Can GenepoweRx and MGI Tech’s AI-Driven Genomic Partnership…
Key Highlights: Strategic Alliance to Revolutionize Genomic MedicineIndian AI-driven startup GenepoweRx and China’s MGI Tech have joined forces…
Bexorg and Biohaven: Can Their AI-Driven Whole-Brain Discovery…
Key Highlights: Strategic Collaboration to Transform CNS TherapeuticsBexorg, a techbio innovator focused on decoding the human brain, has…
Tevogen AI & Microsoft: Will Their AI &…
Key Highlights HQ Expansion to Power AI, Generics & Biosimilar VisionTevogen Bio Holdings Inc. (Nasdaq: TVGN) has more…
AlphaMeld AI and VedTechBio: Can Their AI Alliance…
Key Highlights Strategic Alliance to Bridge AI Discovery and Translational ExecutionAlphaMeld Corporation, a global leader in AI-native drug…
Trending Posts
Latest Stories
Can Novartis’ $480 Million AI Investment in 2025 — Bolstered by Strategic AI Deals — Accelerate Discovery, R&D, and Commercial Leadership in 2026?
Global – December 31, 2025 — Novartis International AG significantly expanded its investment in artificial…
Can Johnson & Johnson’s $350 Million AI Investment in 2025 Transform Drug Discovery, R&D, and Commercial Success in 2026?
Global – December 31, 2025 — Johnson & Johnson significantly expanded its use of artificial…
AbbVie Invested $400 Million in AI in 2025: How This Will Transform Discovery, R&D, and Commercialization in 2026
Global – December 31, 2025 — AbbVie Inc. significantly expanded the integration of artificial intelligence…
Is Eli Lilly’s $450 Million AI Investment in 2025 Set to Transform Drug Discovery, R&D, and Commercialization?
Global – December 31, 2025 — Eli Lilly and Company significantly expanded its artificial intelligence…
Gallery
